12 recruiting, 9 completed, 4 active not recruiting, 4 withdrawn. 37 Phase 2, 16 Phase 1.
Follow PM 01183: new trials by email Literature Review of PM 01183 trials Research Report on PM 01183
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer Lurbinectedin, Paclitaxel - Carcinoma, Small Cell Lung | Phase 2 | Not yet recruiting | Yonsei University | 69 | 2026-11-01 | 2026-09-04 |
| Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases Immunotherapy, Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin), low-dose radiation - Lung Cancer (SCLC) | Phase 2 | Not yet recruiting | Sichuan University | 30 | 2026-10-31 | 2026-05-05 |
| A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC Lurbinectedin, Durvalumab - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 50 | 2026-10-12 | 2026-11-06 |
| Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC Stenoparib/Temozolomide, Lurbinectedin - Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | VA Office of Research and Development | 166 | 2026-02-23 | 2026-03-11 |
| An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide - SCLC, Extensive Stage | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 100 | 2025-12-31 | 2025-08-26 |
| An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment Lurbinectedin, Radiation Therapy - Small Cell Lung Carcinoma | Phase 2 | Active not recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 9 | 2025-12-31 | 2026-06-16 |
| A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer ABBV-706, Atezolizumab, Etoposide - Small Cell Lung Cancer | Phase 2 | Recruiting | AbbVie | 180 | 2025-11-25 | 2026-10-27 |
| Clinical Study in Adult and Young Adult Patients With Advanced Desmoplastic Small Round Cell Tumor (DSRCT) ISG-TULIPS Lurbinectedin, Irinotecan - Desmoplastic Small Round Cell Tumor | Phase 2 | Recruiting | Italian Sarcoma Group | 20 | 2025-11-21 | 2026-11-03 |
| Patients With High-grade Pancreatic Neuroendocrine Tumors Lurbinectedin 4 MG Injection [Zepzelca] - Neuroendocrine Tumor of Pancreas, Pancreatic Neuroendocrine Tumors | Phase 2 | Enrolling by invitation | National Cancer Center, Korea | 46 | 2025-09-23 | 2025-10-01 |
| Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC Serplulimab, Lurbinectedin, Carboplatin - Extensive-Stage Small Cell Lung Cancer | Phase 2 | Recruiting | Guangzhou Institute of Respiratory Disease | 30 | 2024-12-01 | 2026-06-08 |
| Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas Lurbinectedin, Radiotherapy, Non-investigational surgery - Locally Advanced Soft Tissue Sarcoma | Phase 1 / Phase 2 | Withdrawn | University of California, San Francisco | 2024-10-31 | 2024-11-18 | |
| Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER) Lurbinectedin, Avelumab - Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract | Phase 2 | Recruiting | National Cancer Institute (NCI) | 45 | 2024-06-13 | 2026-11-12 |
| Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer Lurbinectedin, Dostarlimab - Endometrial Cancer | Phase 1 / Phase 2 | Withdrawn | Vall d'Hebron Institute of Oncology | 2024-05-01 | 2025-04-01 | |
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel. - Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC) | Phase 1 / Phase 2 | Recruiting | Phanes Therapeutics | 203 | 2023-09-05 | 2026-07-15 |
| Lurbinectedin in FET-Fused Tumors Lurbinectedin - Ewing Sarcoma, Desmoplastic Small Round Cell Tumor | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 63 | 2023-07-27 | 2026-09-02 |
| LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma Lurbinectedin - Advanced Soft-tissue Sarcoma | Phase 1 / Phase 2 | Unknown | ERLINDA M GORDON | 40 | 2023-06-07 | 2024-07-05 |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma Lurbinectedin - Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | Jazz Pharmaceuticals | 60 | 2023-05-23 | 2026-11-05 |
| Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin - Metastatic Cancer, Urothelial Carcinoma | Phase 2 | Withdrawn | AdventHealth | 2023-05-08 | 2024-08-01 | |
| Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer Carboplatin, Pemetrexed, Paclitaxel - Lung Cancer, Small-cell Lung Cancer | Phase 2 | Recruiting | Fox Chase Cancer Center | 280 | 2023-02-22 | 2026-05-22 |
Showing 20 of 37. Sign in to see all of them.
Small Cell Lung Carcinoma (14) · Lung Neoplasms (4) · Sarcoma (4) · Endometrial Neoplasms (3) · Sarcoma, Ewing (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Desmoplastic Small Round Cell Tumor (2) · Mesothelioma (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Neuroendocrine Tumors (2) · Adenoma, Islet Cell (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Ovarian Epithelial (1)
PharmaMar (5) · Jazz Pharmaceuticals (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Massachusetts General Hospital (2) · National Cancer Institute (NCI) (2) · AbbVie (1) · AdventHealth (1) · Antonio Calles Blanco (1) · Children's Hospital of Philadelphia (1) · ERLINDA M GORDON (1) · Fox Chase Cancer Center (1) · Fundacion Oncosur (1) · Guangzhou Institute of Respiratory Disease (1) · HonorHealth Research Institute (1) · Italian Sarcoma Group (1)
United States (24) · Spain (9) · Italy (5) · China (4) · Germany (3) · South Korea (3) · Switzerland (3) · Belgium (2) · France (2) · Canada (1) · Israel (1) · Japan (1) · Poland (1) · Serbia (1) · Sweden (1)
Anastasios Dimou, MD (1) · Andrea B Apolo, M.D. (1) · Andres Poveda, MD (1) · Anish Thomas, M.D. (1) · Antonio Calles (1) · Erkut Borazanci, MD (1) · Erlinda M Gordon, MD (1) · Federica Grosso, MD (1) · Gregory Cote, M.D. Ph.D (1) · Gregory Cote, MD PhD (1) · Hye Ryun Kim (1) · Jared Weiss, MD (1) · Julia Judd, DO (1)
PMID 30240327, PMID 31896519, PMID 32085891, PMID 32224306, PMID 33096421, PMID 33914350, PMID 34739582, PMID 35486638, PMID 35830841, PMID 36037567, PMID 37491889, PMID 37556023, PMID 38964333, PMID 39490738, PMID 39938593, PMID 40116623, PMID 40963055, PMID 41791703, PMID 42081171
2017 (1), 2025 (1)